AIM:To analyze the clinical efficacy of Ranibizumab in the treatment of wet age-related macular degeneration(ARMD).

METHODS: Clinical data of patients with wet age-related macular degeneration received treatment of ranibizumab at our hospital from 2015 to 2017 were analyzed. At 1mo after treatment, the clinical efficacy, ocular hemodynamics and ocular inflammation were evaluated.

RESULTS: A total of 41 patients were analyzed. After treatment, patients got significantly increased in LogMAR(0.651±0.067 vs 0.321±0.049; t=25.460, P<0.01)and decreased in central foveal thickness(239.1±51.9μm vs 452.9±69.8μm; t=15.740, P<0.01). There was no serious complication during treatment period. After treatment, the levels of TNF-α(13.1±4.1ng/L vs 16.1±3.5ng/L; t=3.563, P<0.01)and IL-6(12.1±1.9ng/L vs 13.8±2.5ng/L; t=3.467, P<0.01)in aqueous fluid decreased significantly. There was no significantly changes of blood flow volume of central retinal artery and ophthalmic artery at peak systolic velocity and end diastolic velocity before and after treatment(P>0.05).

CONCLUSION: In the treatment of wet age-related macular degeneration, the ranibizumab shows a good therapeutic effect without serious adverse drug reactions.